The biopharmaceutical industry is at a critical juncture, facing the pressing need to incorporate sustainability into its growth and innovation strategies. The rise of artificial intelligence (AI) presents both opportunities and challenges in this quest. While AI has demonstrated a profound ability
The biotech industry is at a crossroads, grappling with the challenges and expectations set by cell therapies. Oncology-focused treatments that once held great promise are now facing a reality check, prompting many companies to reevaluate their focus on autoimmune diseases. As expectations align
The quest for effective treatments in the fight against metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic steatohepatitis (NASH), has reached an exciting new threshold. Boehringer Ingelheim has shared groundbreaking results from their Phase II clinical
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's own
In a significant stride for medical science, PhoreMost Ltd., a biotechnological innovator, has forged a promising path in retinal therapy through its alliance with the pharmaceutical giant Boehringer Ingelheim. The joint venture, which kicked off in January 2020, has recently celebrated a crucial
